Taken together, these results demonstrate that the expression of the Carmil2QE mutation in and only in cancer-specific CD8+ T cells sufficed to trigger their intratumoral expansion, resulting in protective T cell–mediated anticancer immunity without the need for anti-PD-1 therapy. The gene discussed is CD8A; the disease is cancer.